Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer to Perform Proteomics Analysis in Alzheimer s Research Partnership

NEW YORK, April 15 - PerkinElmer said today that it has entered a research collaboration with the Rush Alzheimer's Disease Center and the Buck Institute for Age Research to identify protein and gene targets involved in the onset and progression of Alzheimer's disease.


The Rush Alzheimer's Disease Center will supply brain tissue samples from patients who agreed to detailed annual clinical evaluations and brain donation at the time of death. The Buck Institute will perform genomic analysis on the tissue and PerkinElmer will perform proteomic studies to identify differentially expressed proteins in Alzheimer's and normal human brain tissue.


PerkinElmer and the Buck Institute said they would release their findings in a paper to be submitted later this year.


The proteomic analysis will be performed in PerkinElmer's Boston facility, and will involve up to 30 scientists led by Mary Lopez, director of biochemistry at PerkinElmer Life and Analytical Sciences.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.